Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Monopar Therapeutics Inc.NASDAQ: MNPR
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $0 a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Net receivables amounts to 0.0% of total assets for MNPR, versus a peer median of 5.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $413.86M USD | +1310.0% | -48.2% | 35.2% | |
| Jun 2026 | $42.23M USD | -11.2% | +0.3% | 5.8% | |
| Mar 2026 | $40.92M USD | -11.8% | +18.8% | 6.3% | |
| Mar 2026 | $31.05M USD | -2.3% | -26.4% | 10.7% | |
| Mar 2026 | $10.43M USD | -1.1% | -38.0% | 4.8% | |
| Dec 2025 | €7.61M EUR | +363.2% | +34.3% | 12.1% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MNPR) | — | -2.3% | -13.0% | 5.3% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.